ClinicalTrials.gg
RecruitingNCT06821945Updated Sep 15, 2025

A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia

A Phase 2 interventional study of BR5402A and BR5402A-1 in Schizophrenia, sponsored by Boryung Pharmaceutical Co., Ltd. Recruiting at 2 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Boryung Pharmaceutical Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 112 studies in Schizophrenia with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Schizophrenia · Korea, Republic of.

Planned enrollment
60th of 89
120 · median 291
Started
2025
the only one that year
Phase 2
8 of 112
1 open now
Registered
111th of 112
by date

Among the 112 studies in Schizophrenia with a site in Korea, Republic of, this one is the 60th largest by planned enrollment of the 89 interventional ones that give a count, is the only one that started in 2025, is one of 8 in phase 2, and was the 111th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 112 studies in Schizophrenia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Schizophrenia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The objective of this clinical trial is to evaluate the safety and efficacy of olanzapine titration schedule in patients with schizophrenia

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Of patients with schizophrenia in accordance with DSM()-5 diagnostic criteria, who are judged that administration of low dose is more appropriate than initial recommended dose or standard titration dose of olanzapine to consider medical conditions by investigator
  • Patients with the duration of schizophrenia for more than 1 year at screening visit(Visit 1)

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed schizophrenia spectrum and other psychotic disorder(e.g. schizoaffective disorder, etc.), bipolar disorder, depressive disorder, etc., in accordance with DSM()-5 diagnostic criteria at screening visit(Visit 1)
  • Patients with a history of hospitalization for worsening schizophrenia within 12 weeks at screening visit(Visit 1)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Gradual titration group

    Drug: BR5402A · Drug: BR5402B · Drug: BR5402C · Drug: BR5402C-1 · Drug: BR5402D · Drug: BR5402D-1

  • Active comparator
    Conventional titration group

    Drug: BR5402A-1 · Drug: BR5402B-1 · Drug: BR5402C · Drug: BR5402C-1 · Drug: BR5402D

Interventions

  • DrugBR5402A

    Subjects take the investigational products once a day

  • DrugBR5402A-1

    Subjects take the investigational products once a day

    Also known as: Placebo of BR5402A

  • DrugBR5402B

    Subjects take the investigational products once a day

  • DrugBR5402B-1

    Subjects take the investigational products once a day

    Also known as: Placebo of BR5402B

  • DrugBR5402C

    Subjects take the investigational products once a day

  • DrugBR5402C-1

    Subjects take the investigational products once a day

    Also known as: Placebo of BR5402C

  • DrugBR5402D

    Subjects take the investigational products once a day

  • DrugBR5402D-1

    Subjects take the investigational products once a day

    Also known as: Placebo of BR5402D

06

What researchers measure

Primary outcomes

  1. The mean change of PANSS(Positive and Negative Syndrome Scale) total score

    Time frame: 1, 2, 3, 5, 9 weeks from baseline(Visit 2)

  2. Incidence of treatment-emergent adverse events

    Time frame: From the administration of investigational products prescribed at baseline(Visit 2) to 11 weeks(Visit 8)

07

Study locations

1 of 2 sites recruiting
  • Kyungbook National university hospital
    Daegu, South Korea
    Recruiting
    • Seung-hee Won · Contact
  • Hanyang University Guri Hospital
    Guri-si, South Korea
    Not yet recruiting
    • JoonHo Choi · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's planned 24 months is above that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Feb 12, 2025
StartActual
May 30, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06821945
Responsible party
Sponsor
First posted
Feb 12, 2025
Start date
May 30, 2025
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Sep 15, 2025

Study contacts

Shin-young Oh
Contact
syoh@boryung.co.kr
+82+2-708-8000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion